Skip to Main Content

Red flags aplenty are sprouting from the clinical trial results disclosed by Lipocine (LPCN) on Thursday.

Lipocine’s stock price rose by nearly half after the small biotech issued a press release touting “meaningful” reductions in liver fat demonstrated by its experimental pill in a clinical trial. The data don’t hold up to scrutiny.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!